By Professor Janaki Amin

Journal articles

Adetunji AA; Kuti MA; Audu RA; Muyibi SA; Imhansoloeva M; Mosuro OA; Solanke EA; Akpa OM; Irabor AE; Ladipo MMA; Berzins B; Robertson K; Ogunniyi A; Adewole IF; Taiwo BO, 2018, 'Discordant rapid HIV tests: lessons from a low-resource community', HIV Medicine, 19, pp. 72 - 76, http://dx.doi.org/10.1111/hiv.12541

Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Alberto Arnaiz J; Cooper D; Rockstroh JK; Mallon P; Emery S; Fisher M; Rockstroh J; Stellbrink J; Merlin K; Yeung J; Fsadni B; Marks K; Suzuki K; Rismanto N; Salomon H; Rubio AE; Chibo D; Birch C; Swenson L; Chan D; Berg T; Obermeier M; Schuelter E; Aragon SS; Luebke N; Coughlan S; Dean J; Iwatani Y; Teran GR; Avila S; Sirivichayakul S; Naphassanant M; Ubolyam S; Kaye S; Land S; Walker S; Haubrich R; DeJesus E; Berthon-Jones N; Espinosa N; Courtney-Vega K; Absar N; Haskelberg H; Robson R; Donaldson A; Guelman D; Gambardella L; Valdovinos M; Arnaiz J; Beleta H; Ramos N; Targa M; Späth B; Boesecke C; Engelhardt A; Perry N; Beckthold B; Drummond F; Lefevre E; Corr S; Grant C; Lupo S; Peroni L; Sanchez M; De Paz Sierra M; Viloria G; Parlante A; Bissio E; Luchetti P; Confalonieri V; Warley E; Vieni I; Vilas C; Zarate A; Mayer G; Elliot J; Hagenauer M; Kelley M; Bloch M; Cooper D, 2018, 'Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study', HIV Medicine, 19, pp. 65 - 71, http://dx.doi.org/10.1111/hiv.12532

Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression', Journal of Hepatology, 67, pp. 1204 - 1212, http://dx.doi.org/10.1016/j.jhep.2017.07.025

Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040

Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020

Madhavi V; Wines BD; Amin J; Emery S; Lopez E; Kelleher A; Center RJ; Mark Hogarth P; Chung AW; Kent SJ; Stratov I, 2017, 'HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV', Journal of Virology, 91, pp. 10.1128/jvi.00700 - 10.1128/jvi.00717, http://dx.doi.org/10.1128/JVI.00700-17

Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J; Haber P; Rawlinson W; Treloar C; Maher L, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, 24, pp. 733 - 741, http://dx.doi.org/10.1111/jvh.12701

Lee WS; Kristensen AB; Rasmussen TA; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Mark Hogarth P; Reynaldi A; Davenport MP; Emery S; Amin J; Cooper DA; Kan VL; Fox J; Gruell H; Parsons MS; Kent SJ, 2017, 'Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption', Journal of Virology, 91, pp. 10.1128/jvi.00603 - 10.1128/jvi.00617, http://dx.doi.org/10.1128/JVI.00603-17

Madhavi V; Kulkarni A; Shete A; Lee WS; McLean MR; Kristensen AB; Ghate M; Wines BD; Hogarth PM; Parsons MS; Kelleher A; Cooper DA; Amin J; Emery S; Thakar M; Kent SJ, 2017, 'Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts', Journal of Acquired Immune Deficiency Syndromes, 75, pp. 345 - 353, http://dx.doi.org/10.1097/QAI.0000000000001380

Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore GJ; Applegate TL, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', Lancet Gastroenterology and Hepatology, 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4

Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J; Shaw I; Siriragavan S; Horschik T; Sharma S; Eevers A; Andreassen J; Melkeraaen I; Widder N; Lesneuck K; Kotsoros B; Hazelwood S; Holland R; Axten D; Von Bibra S; Powis J; Mason K; Ryder S; Jack K; Scheidegger C; Huber C; Ferguson C; Staehelin C; Lacalamita M; Fragomeli V; Sevehon A, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, 17, pp. 420, http://dx.doi.org/10.1186/s12879-017-2517-3

Teeraananchai S; Kerr SJ; Amin J; Ruxrungtham K; Law MG; Han A, 2017, 'Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis', HIV Medicine, 18, pp. 256 - 266, http://dx.doi.org/10.1111/hiv.12421

Lau A; Kong F; Fairley CK; Donovan B; Chen M; Bradshaw C; Boyd M; Amin J; Timms P; Tabrizi S; Regan DG; Lewis DA; McNulty A; Hocking JS, 2017, 'Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol', BMC Infectious Diseases, 17, pp. 35, http://dx.doi.org/10.1186/s12879-016-2125-7

Boyd MA; Amin J; Mallon PWG; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA, 2017, 'Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study', Lancet HIV, 4, pp. e13 - e20, http://dx.doi.org/10.1016/S2352-3018(16)30189-8

Hajarizadeh B; Grebely J; McManus H; Estes C; Razavi H; Gray RT; Alavi M; Amin J; McGregor S; Sievert W; Thompson A; Dore GJ, 2017, 'Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment', Journal of Gastroenterology and Hepatology Australia, 32, pp. 229 - 236, http://dx.doi.org/10.1111/jgh.13453

Amara AB; Else LJ; Carey D; Khoo S; Back DJ; Amin J; Emery S; Puls RL, 2017, 'Comparison of dried blood spots versus conventional plasma collection for the characterization of efavirenz pharmacokinetics in a large-scale global clinical trial-the ENCORE1 study', Therapeutic Drug Monitoring, 39, pp. 654 - 658, http://dx.doi.org/10.1097/FTD.0000000000000448

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2017, 'Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014)', Hepatology Communications, 1, pp. 736 - 747, http://dx.doi.org/10.1002/hep4.1073

Lee WS; Kristensen AB; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Hogarth PM; Reynaldi A; Davenport M; Emery S; Amin J; Cooper DA; Kan V; Fox J; Grüll H; Parsons MS; Kent SJ; Rasmussen TA, 2017, '13 HIV-1-specific ADCC following anti-latency therapy and analytical treatment interruption', Journal of Virus Eradication, 3, pp. 10, http://dx.doi.org/10.1016/s2055-6640(20)30718-4

Alavi M; Amin J; Grebely J; Law MG; Janjua NZ; Krajden M; Hajarizadeh B; George J; Matthews GV; Larney S; Degenhardt L; Dore GJ, 2017, 'O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study', Journal of Virus Eradication, 3, pp. 9, http://dx.doi.org/10.1016/s2055-6640(20)30906-7

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study', Journal of Virus Eradication, 3, pp. 2 - 3, http://dx.doi.org/10.1016/s2055-6640(20)30889-x

Cunningham E; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Hajarizadeh B; Dore GJ; Lloyd A; Grebely J, 2017, 'P10 Injecting risk behaviours among people who inject drugs in an Australian prison setting, 2005–2014: the HITS-p study', Journal of Virus Eradication, 3, pp. 15 - 16, http://dx.doi.org/10.1016/s2055-6640(20)30751-2

Moore CL; Grulich AE; Prestage G; Gidding HF; Jin F; Petoumenos K; Zablotska IB; Poynten IM; Mao L; Law MG; Amin J; Han A, 2016, 'Hospitalization for anxiety and mood disorders in HIV-infected and -uninfected gay and bisexual men', Journal of Acquired Immune Deficiency Syndromes, 73, pp. 589 - 597, http://dx.doi.org/10.1097/QAI.0000000000001147

Moore CL; Grulich AE; Prestage G; Gidding HF; Jin F; Petoumenos K; Zablotska IB; Poynten IM; Mao L; Law MG; Amin J, 2016, 'Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men.', J Acquir Immune Defic Syndr, 73, pp. 589 - 597, http://dx.doi.org/10.1097/QAI.0000000000001147

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ; Han A, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010

Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ; Han A, 2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, 65, pp. 879 - 887, http://dx.doi.org/10.1016/j.jhep.2016.06.025

Moore CL; Gidding HF; Jin F; Mao L; Petoumenos K; Zablotska IB; Poynten IM; Prestage G; Law MG; Grulich AE; Amin J; Han A, 2016, 'Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men', AIDS and Behavior, 20, pp. 2372 - 2386, http://dx.doi.org/10.1007/s10461-016-1303-3

Achhra AC; Mwasakifwa G; Amin J; Boyd MA, 2016, 'Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis', Lancet HIV, 3, pp. e351 - e360, http://dx.doi.org/10.1016/S2352-3018(16)30015-7

Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R, 2016, 'Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study', Clinical Pharmacokinetics, 55, pp. 861 - 873, http://dx.doi.org/10.1007/s40262-015-0360-5

Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S; Cooper D; Haskelberg H; Absar N, 2016, 'Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: Week 48 Results of the randomized, multicenter March study', Clinical Infectious Diseases, 63, pp. 122 - 132, http://dx.doi.org/10.1093/cid/ciw207

Moore CL; Gidding HF; Law MG; Amin J; Han A, 2016, 'Poor record linkage sensitivity biased outcomes in a linked cohort analysis', Journal of Clinical Epidemiology, 75, pp. 70 - 77, http://dx.doi.org/10.1016/j.jclinepi.2016.01.023

Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Applegate TL; Grebely J; Dolan K, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, 16, pp. 241, http://dx.doi.org/10.1186/s12879-016-1567-2

Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, 13, pp. 32, http://dx.doi.org/10.1186/s12985-016-0482-x

Martinello M; Amin J; Matthews GV; Dore GJ, 2016, 'Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia pacific region: A systematic review and meta-analysis', AIDS Reviews, 18, pp. 69 - 80

Moore CL; Grulich AE; Prestage G; Gidding HF; Jin F; Mao L; Petoumenos K; Zablotska IB; Poynten IM; Law MG; Amin J, 2016, 'Hospitalisation rates and associated factors in community‐based cohorts of HIV‐infected and ‐uninfected gay and bisexual men', HIV Medicine, 17, pp. 327 - 339, http://dx.doi.org/10.1111/hiv.12312

Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA, 2015, 'Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 ))', Plos One, 10, pp. e0140623, http://dx.doi.org/10.1371/journal.pone.0140623

Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J; Marks P; Amin J; Doab A; Carroll T; Teutsch S; Li H; Oon A; Cameron B; Lloyd A; White P; Rawlinson W; Jacqueline Flynn ; Goy K; Nguyen O; von Bibra S; Ffrench R; McCaughan G; Madden A; Farrell G; Crofts N; Sievert W; Baker D; Jacka B; Pan Y; Shaw D; Sasadeusz J; Crawford D; Phung N; George J; Bloch M; Hughes B; Mollison L; Roberts S; Desmond P, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, 26, pp. 976 - 983, http://dx.doi.org/10.1016/j.drugpo.2015.05.003

Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R, 2015, 'Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study', Clinical Pharmacology and Therapeutics, 98, pp. 406 - 416, http://dx.doi.org/10.1002/cpt.156

Vajdic CM; Marashi Pour S; Olivier J; Swart A; O'Connell DL; Falster MO; Meagher NS; Mao L; Grulich AE; Randall DA; Amin J; Burns L; Degenhardt L, 2015, 'Corrigendum to "The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort study" [Drug Alcohol Depend. 152C (2015) 264-271] DOI: 10.1016/j.drugalcdep.2015.03.026', Drug and Alcohol Dependence, 154, pp. 304, http://dx.doi.org/10.1016/j.drugalcdep.2015.06.024

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; InC , 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study', Journal of Viral Hepatitis, 22, pp. 708 - 717, http://dx.doi.org/10.1111/jvh.12384

Lamoury FMJ; Jacka B; Bartlett S; Bull RA; Wong A; Amin J; Schinkel J; Poon AF; Matthews GV; Grebely J; Dore GJ; Applegate TL, 2015, 'The influence of hepatitis C virus genetic region on phylogenetic clustering analysis', Plos One, 10, pp. e0131437, http://dx.doi.org/10.1371/journal.pone.0131437

Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Nwizu C; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Avihingsanon A; Boyd M; Carey D; Clarke A; Courtney-Vega K; Delfino M; Donaldson A; Emery S; Espinosa N; Johannesen T; Lin E; Losso M; Moricz A; Pett S; Phanupak P; Puls R; Pussadee K; Sutheerasak P; Tomlins L; Ubolyam S; bin Raja Azwa RIS; Bissio E; Calanni L; Chetchotisakd P; Doong N; Elliott J; Gazzard B; Kelly M; Laplume H; del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Phanuphak P; Rockstroh J; Rowling D; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Dunn D; Dolan M; Kelleher A, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', Lancet Infectious Diseases, 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5

Vajdic CM; Pour SM; Olivier J; Swart A; O'Connell DL; Falster MO; Meagher NS; Mao L; Grulich AE; Randall DA; Amin J; Burns L; Degenhardt L, 2015, 'The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort study', Drug and Alcohol Dependence, 152, pp. 264 - 271, http://dx.doi.org/10.1016/j.drugalcdep.2015.03.026

Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK; PINT study team , 2015, 'Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.', AIDS, 29, pp. 911 - 919, http://dx.doi.org/10.1097/QAD.0000000000000625

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Dore GJ; Grebely J, 2015, 'Patterns of hepatitis C Virus RNA levels during acute infection: The InC3 study', Plos One, 10, pp. e0122232, http://dx.doi.org/10.1371/journal.pone.0122232

Winston A; Amin J; Clarke A; Else L; Amara A; Owen A; Barber T; Jessen H; Avinghsanon A; Chetchotisakd P; Khoo S; Cooper DA; Emery S; Puls R; Carey D; Cunningham P; Kelleher A, 2015, 'Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: A randomized controlled trial', Clinical Infectious Diseases, 60, pp. 1026 - 1032, http://dx.doi.org/10.1093/cid/ciu976

Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA, 2015, 'Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection', Plos One, 10, pp. e0118228, http://dx.doi.org/10.1371/journal.pone.0118228

Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA, 2015, 'Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis', Lancet HIV, 2, pp. e42 - e51, http://dx.doi.org/10.1016/S2352-3018(14)00061-7

Lee FJ; Amin J; Carr A, 2015, 'Limited reporting of major harms in studies of initial combination antiretroviral therapy: A systematic review', AIDS, 29, pp. 921 - 929, http://dx.doi.org/10.1097/QAD.0000000000000633

Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ; Han A, 2015, 'Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment', Journal of Hepatology, 62, pp. 269 - 277, http://dx.doi.org/10.1016/j.jhep.2014.09.001

Larney S; Grebely J; Falster M; Swart A; Amin J; Degenhardt L; Burns L; Vajdic C, 2015, 'Diagnosis of hepatitis c virus infection after entry to opioid substitution therapy', Drug and Alcohol Dependence, 156, pp. e122, http://dx.doi.org/10.1016/j.drugalcdep.2015.07.337

Back to profile page